Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 1,667,012 | 1,561,392 | 992,550 | 1,502,179 | 1,172,982 | 6,896,115 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 1,667,012 | 1,561,392 | 992,550 | 1,502,179 | 1,172,982 | 6,896,115 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 3,081,244 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 3,814,871 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 1,667,012 | 1,561,392 | 992,550 | 1,502,179 | 1,172,982 | 6,896,115 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 27,434 | 28,028 | 20,513 | 137 | 7,492 | 83,604 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 106 | 32,151 | 100 | 7,260 | 8,954 | 48,571 |
| 11 | Total support. Add lines 7 through 10 | 7,028,290 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2022 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2022 |
(iii) Distributable Amount for 2022 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2022 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2022: | ||||
| a From 2017....... | ||||
| b From 2018....... | ||||
| c From 2019....... | ||||
| d From 2020....... | ||||
| e From 2021....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2022 distributable amount | ||||
|
i
Carryover from 2017 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2022 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2022 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2023. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2018..... | ||||
| b Excess from 2019..... | ||||
| c Excess from 2020..... | ||||
| d Excess from 2021..... | ||||
| e Excess from 2022..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4A | 2022 ACCOMPLISHMENTS: 1. REGIONAL LIFE SCIENCES STRATEGIC ASSESSMENT "PATH TO 2025" 2. 2021 KANSAS CITY REGIONAL LIFE SCIENCES CENSUS 3. KANSAS CITY QUALITY AND VALUE INNOVATION CONSORTIUM (KC QVIC)/HEALTHCARE INSTITUTE FOR INNOVATIONS IN QUALITY (HI-IQ) 4. KANSAS CITY REGIONAL BIOLOGICS RESEARCH AND DEVELOPMENT INVENTORY 5. ETHICAL ARTIFICIAL INTELLIGENCE (AI) 6. HEALTH EQUITY LEARNING AND ACTION NETWORK (HE-LAN) 7. DIVERSITY, EQUITY AND INCLUSION (DEI) 8. RESEARCH DEVELOPMENT GRANT PROGRAMS 9. KC NEXUS FUND 10. WORKFORCE DEVELOPMENT 11. FOCUS FORWARD ON THE FUTURE OF KC 12. "SCIENCE2ART" 13. EVENTS: -NEXUS INFORMATICS -ONE HEALTH DAY 14. SOCIAL MEDIA -CONNECTION -EXPERT EXCHANGE 1. REGIONAL LIFE SCIENCES STRATEGIC ASSESSMENT: "PATH TO 2025" THE PATH TO 2025, A 10-YEAR STRATEGIC ROADMAP FOR THE KC REGION WAS DEVELOPED COLLABORATIVELY WITH THE COMMUNITY IN 2015. NEARLY EIGHT YEARS IN, THE REPORT REMAINS THE LENS BIONEXUS KC APPLIES TO ITS WORK AND PRIORITY FOCUS AREAS. THIS REPORT HIGHLIGHTS SCIENTIFIC FOCUS AREAS OF OPPORTUNITY, INCLUDING ANIMAL HEALTH, HEALTH IT AND OUTCOMES RESEARCH, CANCER AND NEUROSCIENCE, AS WELL AS COMPONENTS OF THE REGIONAL INFRASTRUCTURE THAT NEEDED TO BE STRENGTHENED TO ALLOW FOR ROBUST REGIONAL GROWTH, INCLUDING COLLABORATION, CAPITAL, WORKFORCE DEVELOPMENT AND MESSAGING/MARKETING. IN 2022, THE FOUR SCIENTIFIC AREAS CONTINUED TO BE ADVANCED AREAS OF EXPERTISE AND OPPORTUNITY. THE KU CANCER CENTER, A REGIONAL, COLLABORATIVE EFFORT IN WHICH BIONEXUS KC PLAYED AN IMPORTANT ROLE EARLY ON, WAS AWARDED NCI COMPREHENSIVE CANCER CENTER DESIGNATION, A HIGHLY COVETED RECOGNITION THAT WILL EXPAND RESEARCH, ACCESS, AND IMPACT TO PATIENTS ACROSS THE COUNTRY. IN HEALTHCARE IT, BIONEXUS KC CATALYZED THE CREATION OF AN INITIATIVE AROUND DIGITAL HEALTH TO SOLVE HEALTHCARE'S BIGGEST CHALLENGES AND CONNECT IDEAS, TALENT, CAPITAL, AND COMPANIES TO MAKE IMPACTFUL ADVANCEMENTS. THE PATH TO 2025 CONTINUED TO EVOLVE AND NEW PRIORITIES WERE IDENTIFIED BY REGIONAL PARTNERS INCLUDING HEALTH EQUITY, DEI (DIVERSITY, EQUITY, AND INCLUSION), RARE DISEASE AND BIOLOGICS, WHICH CUT ACROSS ALL FOUR SCIENTIFIC AREAS AND ARE NOW KEY AREAS OF FOCUS. WHILE ANIMAL HEALTH IS NOT DIRECTLY CALLED OUT IN THESE NEW AREAS OF OPPORTUNITY, THE REGION CAN LEVERAGE ITS LONGSTANDING STRENGTHS TO DEVELOP UNIQUE ASSETS AND PERSPECTIVES TO ACCELERATE INNOVATION FOR BOTH HUMAN AND ANIMAL PATIENTS. COLLABORATING AND CONVENING THE REGION IN UNIQUE AND EFFECTIVE WAYS REMAINED A FOCAL POINT FOR BIONEXUS KC. THE INSTITUTIONAL ADVISORY COMMITTEE, LIFE SCIENCES COMMUNICATORS, AND DEI COMMITTEE UNITED STAKEHOLDERS AND IDENTIFIED JOINT OPPORTUNITIES. REGIONAL EVENTS, POWERED BY BIONEXUS KC, REPRESENTED KEY GATHERINGS OF RESEARCHERS AROUND PRIORITY TOPICS SHOWCASING REGIONAL STRENGTHS. BIONEXUS KC CULTIVATED A DYNAMIC ECOSYSTEM WITH UNIQUE PARTNERSHIPS TO ADVANCE REGIONAL EFFORTS AND ENSURE THAT 2023 WILL YIELD SIGNIFICANT PROGRESS IN CAPITAL FORMATION, WORKFORCE DEVELOPMENT, AND MARKETING AND MESSAGING. 2. 2021 KANSAS CITY REGIONAL LIFE SCIENCES CENSUS SINCE 2003, BIONEXUS KC HAS COMMISSIONED THE KANSAS CITY REGIONAL LIFE SCIENCES INDUSTRY CENSUS EVERY THREE YEARS TO DEFINE THE COMPOSITION AND SCOPE OF ECONOMIC ACTIVITY IN THIS VITAL SECTOR OF THE ECONOMY. THE UPDATED DATA PROVIDES INSIGHTS THAT CAN INFLUENCE POLICY MAKING, WORKFORCE DEVELOPMENT, AND AREA FUNDING. MOST IMPORTANTLY, IT HELPS IDENTIFY ECONOMIC AND RESEARCH TRENDS THAT WILL HELP STEER THE KC REGION TOWARDS LIFE SCIENCES SUCCESS. THE MOST RECENT VERSION OF THE CENSUS WAS COMPLETED IN DECEMBER 2021 AND FOUND THAT, ACROSS THE 286 COMPANIES IDENTIFIED, THE KC LIFE SCIENCES INDUSTRY EMPLOYS ~35,000 PEOPLE. THE NUMBER OF UNIVERSITY RESEARCH CENTERS ROSE TO 149 IN 2021, AND THE NUMBER OF MEDICAL CENTERS PERFORMING CLINICAL TRIALS INCREASED TO 32. THE FINAL REPORT WAS RELEASED IN JANUARY 2022 AND IS AVAILABLE FOR DOWNLOAD AT TTPS://BIONEXUSKC.ORG/REPORTS/. 3. KANSAS CITY QUALITY AND VALUE INNOVATION CONSORTIUM (KC QVIC) AND THE HEALTHCARE INSTITUTE FOR INNOVATIONS IN QUALITY (HI-IQ) BIONEXUS KC CONTINUED ITS LONGSTANDING SUPPORT OF THE KANSAS CITY QUALITY AND VALUE INNOVATION CONSORTIUM (KC QVIC) WHICH HELPED TRANSITION THE KC QVIC FROM A VISION OF IMPROVING THE EQUITY AND VALUE OF HEALTHCARE IN KANSAS CITY AND REBRANDING AS A NEW UNIT AT UMKC, CALLED THE UMKC HEALTHCARE INSTITUTE FOR INNOVATIONS IN QUALITY (HI-IQ). WITH THE RESOURCES PROVIDED BY BIONEXUS KC, HI-IQ'S TWO TRANSLATIONAL SCIENCE PILOT PROJECTS CONTINUED TO COLLECT VALUABLE, ACTIONABLE INFORMATION. THE PILOT PROJECTS INCLUDED (1) ADDRESSING OPIOID CRISES IN THE EMERGENCY DEPARTMENT AND (2) IMPROVING TRANSITIONS OF CARE FOR HEART FAILURE. BIONEXUS KC PARTICIPATED ON HI-IQ'S STRATEGIC ADVISORY BOARD AND LENT STAFF EXPERTISE TO SUPPORT HI-IQ'S EFFORTS, INCLUDING THE INSTITUTE'S MONTHLY INNOVATIONS IN QUALITY FORUMS (IQ FORUMS). IN 2022, THESE FORUMS ENGAGED OVER 600 REGISTRANTS ON A WIDE VARIETY OF TOPICS INCLUDING: (1) SOCIAL DETERMINANTS OF HEALTH, (2) MATERNAL MORTALITY, (3) RURAL HEALTH AND (4) ALTERNATIVE PAYMENT MODELS. HI-IQ LEVERAGED THE NEARLY $80,000 START-UP GRANT FROM BIONEXUS KC (2021 BIONEXUS KC GRANT) TO SECURE ANOTHER $1.1 MILLION IN GRANT AND PHILANTHROPIC SUPPORT FOR RESEARCH PROJECTS AND LAUNCHED A GRADUATE-LEVEL IMPLEMENTATION SCIENCE COURSE AT UMKC. 4. KANSAS CITY REGIONAL BIOLOGICS RESEARCH AND DEVELOPMENT INVENTORY BIONEXUS KC RECEIVED FUNDING FROM THE KAUFFMAN FOUNDATION TO DEVELOP A REGIONAL ASSESSMENT TO IDENTIFY AND INVENTORY REGIONAL LIFE SCIENCES ORGANIZATIONS PERFORMING RESEARCH AND DEVELOPMENT IN BIOLOGICS TO CREATE A BASELINE TO MEASURE FUTURE GROWTH. THE ASSESSMENT IDENTIFIED NEARLY 120 REGIONAL COMPANIES PERFORMING RESEARCH AND DEVELOPMENT IN BIOLOGICS. THESE COMPANIES ARE PRIMARILY HUMAN HEALTH COMPANIES AND EMPLOY MORE THAN 13,000 PEOPLE ACROSS THE REGION. REGIONAL OPPORTUNITIES WERE IDENTIFIED IN SPECIFIC TECHNOLOGY SECTORS: (1) VACCINES, (2) THERAPEUTIC PROTEINS, (3) CELL/GENE THERAPIES, AND (4) DIAGNOSTICS. IN 2022, KANSAS CITY WAS SELECTED AS ONE OF NINE REGIONS WORLDWIDE TO BE PART OF THE MIT REGIONAL ENTREPRENEURSHIP ACCELERATION PROGRAM (MIT REAP). THE TWO-YEAR PROGRAM ACCELERATES INNOVATION DRIVEN ENTREPRENEURSHIP IN EACH RESPECTIVE INNOVATION ECOSYSTEM. ALONG WITH ORGANIZATIONS FROM ACROSS THE BI-STATE REGION, BIONEXUS KC WAS SELECTED AS A MEMBER OF THE KANSAS CITY MIT REAP TEAM, ULTIMATELY FOCUSED ON BUILDING OUT THE ENTREPRENEURIAL INFRASTRUCTURE TO PROMOTE BIOLOGICS CLUSTER DEVELOPMENT. KANSAS CITY TEAM MEMBERS ATTENDED WORKSHOPS IN BOSTON TO COLLABORATE WITH MIT EXPERTS AND OTHER GLOBAL MIT REAP TEAMS. THESE WORKSHOPS RESULTED IN A REGIONAL STRATEGY TO IDENTIFY NECESSARY ACTIONS AND NEXT STEPS TO GROW THE BIOLOGICS SECTOR AND SECURE SUPPORT FROM ACROSS THE COMMUNITY. 5. ETHICAL AI THE POTENTIAL IMPACT OF ARTIFICIAL INTELLIGENCE (AI) INTEGRATION IS ENORMOUS AS OUR HEALTHCARE SYSTEM WORKS TO PROVIDE CARE FOR MORE PATIENTS WITH FEWER RESOURCES AND CONTINUES TO ADJUST TO THE DYNAMIC REIMBURSEMENT AND REGULATORY LANDSCAPE. MANY SIGNIFICANT CONCERNS AROUND USING AI IN HEALTHCARE DECISION-MAKING REMAIN, INCLUDING BIAS AND DISCRIMINATION, A LACK OF TRANSPARENCY, AND DATA PRIVACY CONCERNS. A NATIONALLY RECOGNIZED KANSAS CITY ORGANIZATION AND A KEY BIONEXUS KC PARTNER, THE CENTER FOR PRACTICAL BIOETHICS, IS LEADING AN ETHICAL AI PROJECT TO CREATE BEST PRACTICES FOR ETHICAL ADHERENCE IN THE DEVELOPMENT, DISSEMINATION, AND USE OF AI SYSTEMS FRAMEWORK. BIONEXUS KC HAS BEEN INVOLVED WITH THE AI PROJECT SINCE IT LAUNCHED IN 2019. AS A FOUNDING MEMBER OF THE ETHICAL AI ADVISORY BOARD, BIONEXUS KC HAS SIGNIFICANTLY GUIDED AND SHAPED THE INITIATIVE. THROUGHOUT 2022, BIONEXUS KC PARTICIPATED IN MONTHLY ADVISORY BOARD MEETINGS AND PARTICIPATED IN A TWO-DAY STRATEGIC PLANNING RETREAT FOCUSED ON FORMALIZING ITS VISION AND MISSION. THE ETHICAL AI PROJECT WILL CURATE AND CREATE CONTENT TO INITIALLY SERVE AS A FOUNDATIONAL LIBRARY OF RESOURCES FOR HEALTHCARE IT COMPANIES AND OTHER STAKEHOLDERS. THE PROJECT WILL ADVANCE THE RESPONSIBLE CREATION AND THOUGHTFUL INTEGRATION OF AI TOWARD POSITIVE AND EQUITABLE HEALTH OUTCOMES. 6. HEALTH EQUITY LEARNING AND ACTION NETWORK (HE-LAN) THE KC HEALTH EQUITY LEARNING AND ACTION NETWORK (KC HE-LAN) UNITED THE REGIONAL HEALTHCARE ECOSYSTEM TO ADDRESS THE FACTORS THAT LEAD TO HEALTH ACCESS, TREATMENT, AND OUTCOME INEQUALITIES. ULTIMATELY, THE KC HELAN WILL CATALYZE EQUITY-CENTERED AND CULTURALLY RESPONSIVE ACTION TO YIELD EQUITABLE HEALTH OUTCOMES FOR ALL. IN 2022, BIONEXUS KC PARTICIPATED IN THE KC HE-LAN DESIGN TEAM TO DEFINE THE NETWORK'S ACTIVITIES AND DELIVERABLES. AS PART OF THE REVIEW TEAM, BIONEXUS KC HELPED IDENTIFY THE PROPOSALS THAT WERE SELECTED TO PARTICIPATE IN THE ACTION PHASE. COMMON TO ALL 15 PROJECTS AND TEAMS WAS A WILLINGNESS TO: (A) ADVANCE EQUITY AND ADDRESS RACISM EXPLICITLY, |
| FORM 990, PART III, LINE 4A | (B) SHARE DATA AND LEARNINGS TRANSPARENTLY, AND (C) SUPPORT PARTICIPATING ORGANIZATIONS. THE KC HE-LAN ASSERTED A COMMON AGENDA ACROSS THE REGION AND PROVIDED COMMUNITY TRAINING, TOOLS, AND EXPERTISE. WITH THE TRANSITION TO THE ACTION PHASE, THE WORK SHIFTED TO OUTCOME-ORIENTED PROJECTS THAT WILL IMPLEMENT MEANINGFUL CHANGES TO SYSTEMS, POLICIES, AND STRUCTURES TO REDUCE AND ELIMINATE DISPARITIES IN HEALTHCARE DELIVERY. THIS PHASE WILL IGNITE MEASURABLE IMPROVEMENTS IN HEALTH OUTCOMES, PARTICULARLY AMONG PEOPLE IMPACTED BY HEALTH INEQUITIES. 7. DEI THE PATH TO 2025 CONTINUED TO EVOLVE AND NEW PRIORITIES WERE IDENTIFIED BY REGIONAL PARTNERS. ONE PRIMARY FOCUS OF MANY REGIONAL ORGANIZATIONS IS HEALTH EQUITY AND DIVERSITY, EQUITY, AND INCLUSION (DEI) INITIATIVES. THE ROLE OF BIONEXUS KC IS TO IMPROVE OUTCOMES FOR ALL AND REDUCE THE INEQUITIES THAT EXIST BETWEEN WHITE AND BLACK KANSAS CITIANS. SCIENTIFIC PRIORITY AREAS OF OPPORTUNITY LIKE RARE DISEASE AND BIOLOGICS CUT ACROSS ALL FOUR SCIENTIFIC AREAS ORIGINALLY INCLUDED AND ARE NOW KEY AREAS OF FOCUS. IN 2022 BIONEXUS KC EXPANDED THE DEI COMMITTEE, COMPOSED OF DEI LEADERS FROM BIONEXUS KC STAKEHOLDER INSTITUTIONS. THE BIONEXUS KC DEI COMMITTEE WILL SERVE AS AN ADVISORY BODY TO REGIONAL HEALTHCARE AND LIFE SCIENCE LEADERSHIP, OFFERING GUIDANCE IN THESE AREAS AS REQUESTED. THE BIONEXUS KC DEI COMMITTEE WILL ALSO INTEGRATE BEST PRACTICES FOR DIVERSITY, EQUITY, AND INCLUSION INTO REGIONAL STAKEHOLDER POLICIES AND PROGRAMS. ADDITIONALLY, THE BIONEXUS KC DEI COMMITTEE WILL PROVIDE EDUCATION AND ENRICHMENT OPPORTUNITIES FOR ITS MEMBERS AND SERVES AS A FORUM FOR DISCUSSION OF SUBSTANTIVE BEST PRACTICES. 8. BIONEXUS KC RESEARCH GRANTS PROGRAM THE BIONEXUS KC RESEARCH GRANTS PROGRAM ACCELERATES REGIONAL LIFE SCIENCES AND HEALTHCARE INNOVATION BY HELPING RESEARCHERS DEMONSTRATE PROOF OF CONCEPT FOR EARLY-STAGE WORK. THE PROGRAM LEVERAGES PARTNERSHIPS WITH FUNDERS AND PROVIDES APPLICANTS WITH THE REVIEW INFRASTRUCTURE BUILT BY BIONEXUS KC FOR RESEARCHERS TO GENERATE PRELIMINARY DATA TO DEVELOP COMPETITIVE GRANT PROPOSALS FOR LARGER FUNDING OPPORTUNITIES. THE PROGRAM BOASTS AN INCREDIBLE RECORD OF SUCCESS FOR EVERY $1 GIVEN OUT IN GRANTS, MORE THAN $13.10 IS RETURNED TO THE REGION IN FOLLOW ON FUNDING. OVER TWO DECADES, BIONEXUS KC HAS PROVIDED MORE THAN $6.7 MILLION IN RESEARCH GRANTS, RESULTING IN MORE THAN $91.8 MILLION OF NEW EXTERNAL RESEARCH FUNDING TO THE REGION. IN 2022, BIONEXUS KC PARTNERED WITH THE PAUL PATTON TRUST, TED C. MCCARTER, WILLIAM EVANS, JR, AND BANK OF AMERICA, N.A. TRUSTEE TO AWARD TWO RESEARCH GRANTS FOCUSED ON THE GENETIC BASIS OF DISEASES THAT AFFECT CHILDREN. BIONEXUS KC ALSO CONTINUED ITS LONG-RUNNING PARTNERSHIP WITH BLUE KC AND ADMINISTERED A ONE-YEAR GRANT TO CONFRONT INEQUITIES IN MATERNAL HEALTHCARE QUALITY AND BIRTH OUTCOMES. THE 2022 BIONEXUS KC RESEARCH DEVELOPMENT GRANT PORTFOLIO INCLUDED: THE BLUE KC TRANSFORMING KC HEALTH RESEARCH GRANT PROGRAM: - ANGELA MARTIN, MD, MEDICAL DIRECTOR, LABOR AND DELIVERY, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, UNIVERSITY OF KANSAS MEDICAL CENTER. DR. MARTIN AND HER TEAM WILL SCREEN BLACK PATIENTS RECEIVING PRENATAL CARE AT THE UNIVERSITY OF KANSAS HEALTH SYSTEM FOR RISK FACTORS THAT INCREASE THEIR RISK OF A POOR BIRTH OUTCOME. THESE RISK FACTORS WILL BE RANDOMIZED, AND THE PATIENTS WILL RECEIVE STANDARD PRENATAL OR DOULA-ENHANCED CARE. MARTIN AND HER TEAM WILL COMPARE RESULTS BETWEEN THESE PATIENTS IN ROUTINE PRENATAL CARE AND DOULA CARE TO RESEARCH WHETHER DOULAS IMPROVE CARE QUALITY AND REDUCE ADVERSE EFFECTS. PAUL PATTON CHARITABLE TRUST GRANTS: - PAMELA TRAN, PHD, ASSOCIATE PROFESSOR, ANATOMY AND CELL BIOLOGY, UNIVERSITY OF KANSAS MEDICAL CENTER. DR. TRAN AND HER TEAM WILL EXAMINE THE BIOLOGICAL PROCESSES OF BONE DEVELOPMENT TO DETERMINE WHICH GENES ARE DEFECTIVE AND LEAD TO DEVELOPING SMALL JAW, A COMMON CRANIOFACIAL ABNORMALITY. THE TEAM WILL ALSO EXPLORE WHETHER VARIANTS IN TWO SPECIFIC GENES CO-OCCUR IN CHILDREN WITH CRANIOFACIAL DEFECTS. - SCOTT YOUNGER, PHD, DIRECTOR OF DISEASE GENE ENGINEERING, DEPARTMENT OF PEDIATRICS, GENOMIC MEDICINE CENTER, CHILDREN'S MERCY KANSAS CITY. DR. YOUNGER AND HIS TEAM WILL DEVELOP HIGH-THROUGHPUT EXPERIMENTAL TECHNOLOGIES FOR EVALUATING THE MOLECULAR CONSEQUENCES OF GENETIC VARIANTS AT SCALE. HIS TEAM WILL UTILIZE THESE TECHNOLOGIES TO PROFILE RARE GENETIC VARIANTS IDENTIFIED AT THE CHILDREN'S MERCY RESEARCH INSTITUTE THROUGH ITS GENOMIC ANSWERS FOR KIDS PROGRAM. 9. KC NEXUS FUND THE KC NEXUS FUND IS A PRIVATELY FUNDED, PROFESSIONALLY MANAGED LIFE SCIENCES PROOF OF CONCEPT FUND THAT FILLS A CRITICAL GAP IN THE REGIONAL ENTREPRENEURIAL ECOSYSTEM. THE DEMAND FOR CAPITAL AND SUPPORT FOR REGIONAL LIFE SCIENCES ENTREPRENEURS CONTINUES TO GROW. AS THE IMPACTS OF THE RECESSION HAVE STRAINED GOVERNMENT PROGRAMS AND RESOURCES, START-UPS HAVE STRUGGLED TO FIND THE CAPITAL NECESSARY TO ADVANCE THEIR INNOVATIONS. INSTITUTIONAL INVESTORS ARE TAKING LESS TECHNOLOGY RISK AND FOCUSING ON EXISTING PORTFOLIO COMPANIES, LEAVING LESS CAPITAL TO ADVANCE EARLY CONCEPTS. START-UPS AND INVESTORS CONTINUE TO LOOK TO BIONEXUS KC AND THE KC NEXUS FUND FOR ASSISTANCE AND GUIDANCE TO NAVIGATE THESE CHALLENGES. IN 2022, THE KC NEXUS FUND MADE PROGRESSIVE STRIDES IN BUILDING THE MODEL, STRUCTURE, AND NETWORK TO POWER ITS VISION BY: -EXPANDING THE NETWORK OF EXPERTS WITH ADVISORS FROM NESTLE-PURINA AND THE AMERICAN KENNEL CLUB. PROVIDING MENTORING AND SUPPORT TO START-UPS THROUGH SOCIAL VENTURE STUDIO, UMKC'S TECHNOLOGY VENTURES STUDIO AND AGLAUNCH PROGRAMS. -ESTABLISHING LEGAL ENTITIES AND ITS MANAGEMENT STRUCTURE. -ADVANCING SEVERAL EARLY-STAGE COMPANIES TOWARDS POTENTIAL INVESTMENT. -INCORPORATING INDUSTRY BEST PRACTICES TO ENSURE DIVERSITY, EQUITY, AND INCLUSION IN OPERATIONS AND PORTFOLIO INVESTMENTS. THE KC NEXUS FUND TEAM PROVIDES MENTORING, GUIDANCE AND CONNECTIONS THAT AID IN CREATING QUALITY LIFE SCIENCES INVESTMENT OPPORTUNITIES FOR REGIONAL INVESTORS AND LIFE SCIENCES COMPANIES. 10. WORKFORCE DEVELOPMENT BIONEXUS KC CONTINUES TO AMPLIFY EFFORTS TO BRING MORE ENGAGEMENT BETWEEN ORGANIZATIONS, INDUSTRY AND EDUCATORS, AND THE ECOSYSTEM. BIONEXUS KC PARTNERS WITH OTHER REGIONAL ORGANIZATIONS TO PROMOTE STEM LEARNING AND BUILD AWARENESS OF CAREERS IN LIFE SCIENCES AMONG ELEMENTARY, MIDDLE, AND HIGH SCHOOL, UNDERGRADUATE, AND GRADUATE STUDENTS. PREP-KC BIONEXUS KC MET WITH PREP-KC LEADERSHIP QUARTERLY AND PARTICIPATED IN PROGRAMMING AIMED AT BOTH STUDENTS AND ADMINISTRATORS. IN 2022, BIONEXUS KC PRESIDENT AND CEO, DENNIS RIDENOUR, JOINED A CAREER PANEL DISCUSSION AS PART OF THE PREP-KC LAUNCH OF THEIR DATA SCIENCE INITIATIVE. BIOKANSAS BIONEXUS KC PROVIDED SCHOLARSHIPS FOR 50 AREA HIGH SCHOOL STUDENTS TO ATTEND THE BIOKANSAS MECHANISMS OF DISEASE RESEARCH AND RECRUITMENT CONFERENCE AS PART OF THE INAUGURAL INNOVATION FESTIVAL. THIS NOVEL CONFERENCE MATCHED EARLY CAREER SCIENTISTS WITH REGIONAL COMPANIES AND INSTITUTIONS, AND EXPOSED THE STUDENTS TO ENGAGING PRESENTATIONS AND WORKSHOPS, AS WELL AS NETWORKING OPPORTUNITIES. GREATER KANSAS CITY SCIENCE AND ENTERTAINMENT FAIR BIONEXUS KC SPONSORED THE 71ST ANNUAL FAIR, WHICH WAS HOSTED VIRTUALLY. IN ADDITION TO THE SPONSORSHIP, BIONEXUS KC LEADERSHIP JUDGED STUDENT POSTERS AND HELPED IDENTIFY TOP ENTRIES. KC STEM ALLIANCE BIONEXUS KC HAS SUPPORTED THE KC STEM ALLIANCE IN ITS WORK TO DEVELOP A REGIONAL, FORMALIZED STEM LEARNING ECOSYSTEM SINCE ITS INCEPTION IN 2015. STEM CONNECT-KC IS AN OPEN, COLLABORATIVE NETWORK THAT SHIFTS THE TRADITIONAL FOCUS FROM THINKING OF EDUCATION AS ONE LEARNING INSTITUTION (SCHOOLS) TO FOCUSING ON THE LEARNER AND PLACES WHERE LEARNING HAPPENS SUCH AS MUSEUMS, LIBRARIES, AFTERSCHOOL PROGRAMS, AND AT HOME. AS PART OF THE STEM CONNECT-KC LEADERSHIP TEAM, BIONEXUS KC AIDS IN PROVIDING LEADERSHIP TO REGIONAL INITIATIVES THAT FOCUS ON IMPROVING QUALITY, ACCESS, AND EQUITY TO STEM PROGRAMS FOR ALL STUDENTS. PROJECT LEAD THE WAY BIONEXUS KC LEADERSHIP PARTICIPATED AS VALIDATION JUDGES FOR THE KC STEM ALLIANCE PROJECT LEAD THE WAY SENIOR SHOWCASE, TO IDENTIFY AND AWARD TOP PRIZES FOR THE BIOMEDICAL RESEARCH COMPETITION 11. FOCUS FORWARD ON THE FUTURE OF KC ON OCTOBER 20, 2022, BIONEXUS KC HOSTED NEARLY 500 LEADERS AND STUDENTS AT THE MIDLAND THEATRE FOR THE FIRST TIME SINCE 2019 TO FOCUS FORWARD ON THE FUTURE OF HEALTHCARE INNOVATION IN KC AND HOW THE REGION CAN MULTIPLY ITS IMPACT. THE PURPOSE OF THIS EVENT WAS TO CONVENE THE REGION'S BRIGHTEST MINDS TO SHARE OUR ACCOMPLISHMENTS, CONNECT THE COMMUNITY, AND PROMOTE COLLABORATION TO ADVANCE ANIMAL AND HUMAN HEALTH. THE EVENT FEATURED DAVID FAJGENBAUM, MD, MBA, MSC, ASSISTANT PROFESSOR OF MEDICINE AT THE UNIVERSITY OF PENNSYLVANIA, AND EXECUTIVE DIRECTOR OF THE CASTLEMAN DISEASE COLLABORATIVE NETWORK. AT 25 YEARS OLD, WHILE IN MEDICAL SCHOOL, HE FELL CRITICALLY ILL, AND HIS DOCTORS COULD NOT |
| FORM 990, PART III, LINE 4A | IDENTIFY THE CAUSE. DR. FAJGENBAUM IS THE NATIONAL BESTSELLING AUTHOR OF 'CHASING MY CURE: A DOCTOR'S RACE TO TURN HOPE INTO ACTION AND A PATIENT BATTLING IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD). HE IS IN HIS LONGEST REMISSION EVER THANKS TO A PRECISION TREATMENT THAT HE IDENTIFIED, WHICH HAD NEVER BEEN USED BEFORE FOR IMCD. HE ALSO LAUNCHED EVERY CURE, A NONPROFIT DEVOTED TO SAVING LIVES BY REPURPOSING EXISTING DRUGS. LEADERS FROM BIONEXUS KC COMMITTEES SHARED THEIR VISION OF THE FUTURE FOR THE LIFE SCIENCES COMMUNITY AND THE AUDIENCE EXPRESSED THEIR PERSPECTIVE ON THE VALUE OF BIONEXUS KC VIA A WORD-CLOUD. 12. "SCIENCE2ART" SCIENCE2ART IS A PLATFORM FOR REGIONAL SCIENTISTS TO DISPLAY AND DESCRIBE THEIR RESEARCH THROUGH THE VISUAL ARTS. EACH OF THESE REMARKABLE PIECES TOLD A PERSONAL RESEARCH STORY AND POETICALLY CAPTURES THE FIELDWORK PERFORMED BY THE SCIENTISTS AND THEIR TEAMS. THESE IMAGES WERE SUBMITTED BY SCIENTISTS FROM COLUMBIA, MISSOURI, TO MANHATTAN, KANSAS. THE 2022 SCIENCE2ART PROGRAM WAS PRESENTED IN TWO PHASES. THE FIRST PHASE WAS AN EXHIBIT IN THE LINDA HALL LIBRARY AND THE SECOND PHASE WAS THE AUCTION AT THE BIONEXUS KC ANNUAL EVENT. ALL PROCEEDS FROM THE SCIENCE2ART AUCTION WERE MATCHED BY BIONEXUS KC AND USED TO SUPPORT STEAM EDUCATION IN KC FOLLOWS: -HIGH SCHOOL PARTICIPATION IN 2022 INNOVATION FESTIVAL'S MECHANISM OF DISEASE RESEARCH AND RECRUITMENT CONFERENCE ORGANIZED BY BIOKANSAS. -PREP-KC -SCIENCE CITY AND THE GREATER KANSAS CITY SCIENCE & ENGINEERING FAIR -FREE EDUCATIONAL PROGRAMS AT THE KEMPER MUSEUM OF CONTEMPORARY ART 13. EVENTS -NEXUS INFORMATICS IN PARTNERSHIP WITH CHILDREN'S MERCY, HOSPITAL BIONEXUS KC HOSTED THE 2022 ANNUAL "NEXUS INFORMATICS CONFERENCE" AT KANSAS CITY UNIVERSITY, WHICH FEATURED A UNIQUE BLEND OF INFORMATICS PERSPECTIVES AND EXPERTISE INDUSTRY, ACADEMIA, MEDICINE, AGRICULTURE, TECHNOLOGY, AND BIOLOGY A TRUE "NEXUS." THE TWO-DAY EVENT GATHERED NATIONAL DATA SCIENCE LEADERS WITH REGIONAL RESEARCHERS, INDUSTRY PROFESSIONALS, AND STUDENTS, CONSISTING OF 10-MINUTE, HIGH-TEMPO, SCIENTIFIC PRESENTATIONS INTERSPERSED WITH NETWORKING OPPORTUNITIES AND A CAREER PANEL. KEYNOTE SPEAKERS INCLUDED WENDY MARIE INGRAM, PHD, CHIEF EXECUTIVE OFFICER AT DRAGONFLY MENTAL HEALTH AND DAN JACOBSON, PHD, CHIEF SCIENTIST, COMPUTATIONAL SYSTEMS BIOLOGY AT OAK RIDGE NATIONAL LABORATORY. INGRAM'S PRESENTATION FOCUSED ON SUPPORTING AND SUSTAINING INCREDIBLE MINDS AND TALENT IN INFORMATICS AND THE STIGMA SURROUNDING MENTAL HEALTH. JACOBSON SHARED HIS RESEARCH IN AGRICULTURE, HUMAN HEALTH, AND IMAGE-BASED PHENOTYPING. THE APRIL 7 8, 2022 CONFERENCE ENCOURAGED CONNECTIONS AND NEW COLLABORATIONS AND HAD A RECORD-HIGH NUMBER OF ATTENDEES, SPEAKERS, AND STUDENT RESEARCH POSTERS EMPHASIZING THE WEALTH OF INFORMATICS INTEREST, CAPABILITIES, AND EXPERTISE IN THE KC REGION. -ONE HEALTH DAY BIONEXUS KC PARTNERED WITH KANSAS STATE UNIVERSITY, KU EDWARDS CAMPUS AND THE UNIVERSITY OF KANSAS MEDICAL CENTER FOR THE NOVEMBER 1, 2022 "KANSAS CITY ONE HEALTH DAY." THIS EVENT IS PART OF AN ANNUAL, INTERNATIONAL EVENT FOCUSED ON COMPLEX COLLABORATIONS ACROSS MULTIPLE DISCIPLINES TO ACHIEVE OPTIMAL HEALTH FOR PEOPLE, ANIMALS, AND THE ENVIRONMENT REFERRED TO AS ONE HEALTH. THE 2022 KC ONE HEALTH DAY'S TOPIC WAS 'MICROPLASTICS,' AN EMERGING CONCERN FOR HUMAN, ANIMAL, AND ENVIRONMENTAL HEALTH. MICROPLASTICS ARE FINE PARTICLES OF PLASTIC (SMALLER THAN ONE MILLIMETER) FOUND IN STREAMS, LAKES, OCEANS, SOIL, AND EVEN AIRBORNE DUST. THEY ARE EVERYWHERE, EVEN THOUGH THEY CAN'T BE SEEN, BUT SUBSTANTIAL RESEARCH REMAINS TO DETERMINE MICROPLASTIC'S SEVERITY AND EFFECTS. THIS EVENT FEATURED A SYNOPSIS OF MICROPLASTICS AND THEIR INFLUENCE ON "ONE HEALTH" BY KEYNOTE BELINDA STRUM, FROM THE UNIVERSITY OF KANSAS. THE PROGRAM ALSO HIGHLIGHTED THE IMPACT MICROPLASTICS HAVE ON AGRICULTURE, THE FOOD WE CONSUME, AND HOW EXPOSURE TO CHEMICALS IN PLASTICIZERS IMPACTS HUMAN HEALTH. THE EVENT HOSTED OVER 100 ACADEMIC AND INDUSTRY ATTENDEES AND FEATURED A POSTER COMPETITION FOR HIGH SCHOOL, UNDERGRADUATE, AND GRADUATE STUDENTS TO COMPETE FOR A CASH SCHOLARSHIP. 14. SOCIAL MEDIA BIONEXUS KC SERVES AS A RESOURCE FOR LIFE SCIENCES NEWS FROM MANHATTAN TO COLUMBIA, USING THE FOLLOWING COMMUNICATION TOOLS: -CONNECTION BLOG: HTTPS://BIONEXUSKC.ORG/CATEGORY/THE-CONNECTION/ -EXPERT EXCHANGE VIDEO SERIES: HTTPS://BIONEXUSKC.ORG/VIDEO_CATEGORY/EXPERT-EXCHANGE/ |
| FORM 990, PART VI, SECTION B, LINE 11B | THE ORGANIZATION HAS A POLICY FOR THE ORGANIZATION'S AUDIT COMMITTEE TO REVIEW THE 990 BEFORE IT IS FILED. |
| FORM 990, PART VI, SECTION B, LINE 12C | ALL STAFF AND DIRECTORS MUST SUBMIT ANY CONFLICTS OF INTEREST ON AN ANNUAL BASIS. IF A CONFLICT ARISES WITHIN THE BOARD, THE DISCLOSING INDIVIDUAL SHALL NEITHER VOTE NOR ENDEAVOR TO INFLUENCE THE DECISION. |
| FORM 990, PART VI, SECTION B, LINE 15A | COMPENSATION OF THE ORGANIZATION'S PRESIDENT IS AGREED UPON BY THE BOARD OF DIRECTORS AND FINALIZED VIA A WRITTEN EMPLOYMENT CONTRACT. THIS APPROVAL IS DOCUMENTED IN THE MINUTES OF THE BOARD. IN 2013 THE ORGANIZATION CREATED A COMPENSATION COMMITTEE AND CONDUCTED A COMPENSATION STUDY TO FURTHER REFINE THE COMPENSATION PROCESS. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE ONLY AVAILABLE UPON REQUEST. |
| FORM 990, PART XII, LINE 1 | THE ORGANIZATION UTILIZES THE MODIFIED CASH BASIS OF ACCOUNTING. UNDER THIS METHOD OF ACCOUNTING, PROPERTY AND EQUIPMENT IS CAPITALIZED AS AN ASSET ON THE STATEMENTS OF ASSETS AND NET ASSETS - MODIFIED CASH BASIS, AND DEPRECIATION EXPENSE AND GAINS AND LOSSES ON DISPOSAL OF PROPERTY AND EQUIPMENT ARE RECORDED ON THE STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET ASSETS - MODIFIED CASH BASIS. ADDITIONALLY, INVESTMENTS ARE RECORDED AS AN ASSET ON THE STATEMENTS OF ASSETS AND NET ASSETS - MODIFIED CASH BASIS, AND GAINS AND LOSSES RELATED TO THE INVESTMENTS ARE RECORDED ON THE STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET ASSETS - MODIFIED CASH BASIS. ALL OTHER ELEMENTS OF THE FINANCIAL STATEMENTS ARE MAINTAINED ON THE CASH BASIS OF ACCOUNTING. |
| FORM 990, PART XXII, LINE 2C | THE ORGANIZATION HAS AN AUDIT COMMITTEE CHARGES WITH FINANCIAL STATEMENT REVIEW. |
| Software ID: | |
| Software Version: |